Neogenomics, Inc.
NEO
$8.75
$0.091.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -73.12% | 63.58% | 39.84% | -73.95% | -69.17% |
| Total Depreciation and Amortization | 0.11% | -0.26% | -4.79% | -2.62% | -2.53% |
| Total Amortization of Deferred Charges | -- | 0.52% | -23.49% | -- | -- |
| Total Other Non-Cash Items | 16.58% | -48.07% | -42.28% | 156.65% | 27.60% |
| Change in Net Operating Assets | -22.77% | -6,820.35% | -101.61% | 146.34% | -643.05% |
| Cash from Operations | -705.88% | -84.88% | -56.30% | 180.27% | -358.44% |
| Capital Expenditure | 36.48% | 5.33% | -31.49% | -40.51% | 61.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | 92.27% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -105.88% | 183.33% | -62.78% | 31.44% |
| Cash from Investing | 20.70% | -2,176.17% | 97.03% | -361.63% | 165.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -18.83% | -- | -- | -73.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Financing | -178.42% | -43.66% | 100.38% | -21,431.19% | 38.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | 45.45% | 140.74% | -- | -- |
| Net Change in Cash | -199.51% | -147.89% | 104.91% | -819.74% | -514.70% |